TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filings

Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, exercised 52,744 restricted share units into ordinary shares on August 3, 2026. He then sold 25,578 ordinary shares at a weighted average of $34.8757 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations related to the RSU vesting.

Teva Pharmaceutical Industries Limited has a holder planning to sell ordinary shares under a resale notice. The plan covers 25,578 ordinary shares to be sold through Citigroup Global Markets, Inc. on or after August 3, 2026, with an indicated aggregate market value of $892,050.65. The shares relate to a Restricted Share Unit Award that vested on August 1, 2022 in respect of services rendered.

Teva Pharmaceutical Industries Limited filed a notice of proposed sale of ordinary shares under Rule 144. The filer plans to sell up to 12,827 ordinary shares through Citigroup Global Markets, Inc. on the NYSE, with an approximate sale date of 08/03/2026.

The shares relate to a Restricted Share Unit Award that vested on 08/01/2024 as compensation for services rendered. The filing lists an aggregate market value of $447,350.60 for the shares and references 1,165,296,084 ordinary shares outstanding as context.

Teva Pharmaceutical Industries Limited reported Q2 2026 net revenues of $4,142 million, roughly flat versus $4,176 million a year earlier, but recorded a net loss attributable to Teva of $576 million, compared with net income of $282 million. The loss reflects sharply higher R&D expense of $970 million, including a $724 million in‑process R&D charge from the Emalex Biosciences acquisition, and $230 million of legal settlements and loss contingencies.

For the first six months of 2026, net revenues were $8,124 million and net loss attributable to Teva was $207 million. Operating cash flow was $371 million, while investing activities used $263 million, largely driven by Emalex. At June 30 2026, cash and cash equivalents were $3,655 million, total assets $39,857 million, total equity $7,757 million, short‑term debt $4,500 million and long‑term senior notes and loans $12,092 million. Teva continues to classify its API business as held for sale, with $1,794 million of related assets and $313 million of liabilities, and maintains a $4,854 million provision for legal settlements and loss contingencies related to ongoing matters.

Teva Pharmaceutical Industries reported Q2 2026 net revenues of $4.14 billion, down 1% year over year, as lower U.S. generics, especially lenalidomide, offset strong growth in key innovative brands. AUSTEDO, AJOVY and UZEDY together generated over $1 billion, growing 43% in local currency.

Teva recorded a GAAP net loss of $576 million, or $0.49 per share, driven by $724 million of acquired IPR&D and $2 million of operating expenses from the $700 million Emalex Biosciences acquisition. Non‑GAAP net income was $21 million with diluted EPS of $0.02; adjusted EBITDA was $474 million versus $1.23 billion a year earlier.

Operating cash flow improved to $411 million and free cash flow to $622 million. For 2026, Teva maintains guidance for revenues of $16.5–$16.85 billion, non‑GAAP EPS of $1.91–$2.11 and free cash flow of $2.0–$2.4 billion, while raising its outlook for AUSTEDO, AJOVY and UZEDY to about $3.7 billion combined. The company also plans to replace its ADS program with a direct NYSE listing of ordinary shares and noted an upgrade of its corporate credit rating to investment grade BBB‑.

Teva Pharmaceutical Industries executive Matthew Shields, EVP of Global Operations, reported an open-market sale of 9,989 Ordinary Shares. The shares were sold at an average price of $32.1901 per share, and his directly held Ordinary Share position is reported as 0 shares following the transaction. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.

TEVA Form 144 notice reports a proposed sale of Ordinary Shares and a recent sale by an affiliated holder. The filing lists a planned disposition through Citigroup Global Markets and records a sale by Matthew Shields of 16,195 shares for $532,329.65 on 06/03/2026. The securities are identified as Ordinary Shares with an associated identifier 9989.

Teva Pharmaceutical Industries EVP and CFO Eliyahu Sharon Kalif sold 106,563 Ordinary Shares in an open-market transaction on June 11, 2026 at a weighted average price of $34.0954 per share. After the sale, he directly holds 65,621 Ordinary Shares.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was scheduled in advance. The filing notes that the price reflects a weighted average from multiple trades between $33.985 and $34.25 per share. Each Ordinary Share may also be represented by one American Depositary Share.

Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales of ordinary shares tied to rollover/compensation transactions and prior dispositions. The filing lists multiple lot sizes dated 03/03/2026 and 03/04/2026, including quantities of 24,900, 33,512, and 23,251 shares. The excerpt also shows 153,251 shares sold during the past three months on 05/14/2026 for $5,457,368.64. The filing names Citigroup Global Markets as a broker and identifies the transactions as compensation ordinary shares or shares from rollover.